Anaemia of Chronic Kidney Disease: What We Know Now

Our understanding of the pathophysiology of the anaemia of chronic kidney disease (CKD) has improved considerably in the last decade with the discovery of the iron regulatory peptide hepcidin. Reduced clearance of hepcidin and the presence of a chronic inflammatory state contribute to elevated hepci...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Renal and Hepatic Disorders 2017-02, Vol.1 (1), p.11-19
Main Authors: Krishnan, Anoushka R., Trinder, Debbie, Chua, Anita C.G., Chakera, Aron, Ramm, Grant A., Olynyk, John K.
Format: Article
Language:English
Subjects:
Anemia
Bacterial infections
Bioavailability
Bone marrow
Cytokines
Enzymes
Hemoglobin
Hypoxia
Inflammation
Iron
Kidney diseases
Kinases
Liver
Metabolism
Mortality
Plasma
Proteins
Regulation
Small intestine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Our understanding of the pathophysiology of the anaemia of chronic kidney disease (CKD) has improved considerably in the last decade with the discovery of the iron regulatory peptide hepcidin. Reduced clearance of hepcidin and the presence of a chronic inflammatory state contribute to elevated hepcidin levels in kidney disease. The recent discovery of the various factors and signalling pathways regulating hepcidin has opened up an exciting avenue for research into the development of newer agents that could treat anaemia of CKD. This review highlights our current understanding of iron metabolism in health, the regulators of hepcidin, issues associated with the current available therapies for the treatment of anaemia in CKD and potential novel therapies that could be available in the near future targeting the various factors that regulate hepcidin.
ISSN:2207-3744
2207-3744
DOI:10.15586/jrenhep.2017.5